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Abstract   
 
Background:  Metabolic syndrome (MetS) and diabetes type 2 (DM2) are increasing in 
incidence in the United States. A recent study found that roughly 34% of the adult 
population meets the criteria for metabolic syndrome. Patients with metabolic syndrome 
were found to have a 3 fold higher incidence of MI, stroke and CHD compared to 
patients without MetS. They were also more likely to develop DM2. Men with metabolic 
syndrome or DM2 also have a higher incidence of hypogonadism. It is estimated that 
37.8% of men >45 years are hypogonadal. Multiple studies have established a link 
between hypogonadism and metabolic syndrome and the next step is to evaluate if raising 
a man’s testosterone levels back to physiologic norms has any benefit in the treatment of 
metabolic syndrome or DM2.   
Methods:  A comprehensive review of the literature was performed using the data bases: 
CINAHL, ovid - Medline, EBMR Multifile, Web of Science, PubMed and Google 
scholar. This produced a number of studies and the following exclusion criteria were 
applied to limit the search. Exclusion criteria: studies in another language, studies not 
using testosterone as a therapy, studies on patients who did not have MetS or DM2, 
studies on women, studies using non-hypogonadal men, studies with a sample size less 
than 15.  
Results:  This resulted in three studies which were evaluated for this review. In all three 
studies evaluated, there was a greater improvement in patients treated with testosterone 
therapy than placebo. In the 52 week study of diet and exercise compared to diet and 
exercise plus testosterone, 62.5% of testosterone patients no longer met the criteria for 
MetS and 87.5% of them reached a HgbA1c goal of <6.5%. The two other studies, which 
only had a treatment phase of 3 months, also had promising results. Both studies 
demonstrated a drop in fasting glucose and insulin levels which corresponded to a 
decrease in HgbA1C. Patients in all three studies had improvements in BMI and waist to 
hip ratio. There were no adverse outcomes reported in any of the studies.   
Conclusion:  Testosterone replacement therapy appears to be beneficial in more places 
than the bedroom. We have yet to discover all effects testosterone replacement has on the 
body, but initial studies are promising. Preliminary studies demonstrate that testosterone 
replacement in hypogonadal men has a greater benefit than risk. It is currently 
recommended to test men with symptoms of hypogonadism, especially if they have 
concurrent MetS or DM2. Returning a man’s T level back to physiologic norms can 
improve MetS and potentially slow its progression to DM2.   
Keywords:  metabolic syndrome, diabetes mellitus type 2, testosterone, therapeutics, and 
hypogonadism 
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The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes 
 
BACKGROUND 
Obesity is becoming a major epidemic as Americans become less active and adopt 
a more sedentary lifestyle. The WHO estimates that globally, there are more than 1 
billion overweight adults, with at least 300 million of them being obese.1 This epidemic is 
currently taking a huge toll on our health care system and it is predicted to only get 
worse. It is estimated that obesity accounts for 2-6% of total health care costs in 
developed nations, but the true cost is likely much higher, as all obesity related illnesses 
are not currently taken into account.1 Obesity is a risk factor for the development of 
diabetes mellitus type 2 (DM2) and a leading component of the metabolic syndrome 
(MetS).   
The constellation of symptoms that is known as MetS increases a person’s risk of 
developing atherosclerotic cardiovascular disease (ASCVD) and DM2.2 The general 
features of MetS as defined by the Adult Treatment Panel III (ATP III) are: abdominal 
obesity, atherogenic dyslipidemia, elevated triglycerides, small LDL particles, low HDL 
cholesterol, raised blood pressure, insulin resistance (± glucose intolerance), a 
prothrombotic state and a proinflammatory state.3 (Table 1) The prevalence of MetS has 
increased over the last few years. The Third National Health and Nutrition Examination 
Survey was performed from 1988-1994 and showed that 22% of US adults met the ATP 
III guidelines for MetS.4 A more recent study 5 conducted from 2003-2006 showed that 
34% of the population 20 years and over met the criteria for MetS. That is a 12% increase 
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in just over 10 years! The incidence of MetS appears to be positively correlated with 
increasing age, and even more dramatically, with increasing BMI.5 Abdominal obesity 
appears to be the most common risk factor, with 30% of overweight males and 65% of 
obese males meeting the criteria.5 Incidence also increased with age, 41% of males 40-59 
years of age and 52% of males aged 60 years or older also met the criteria.5 As our 
society grows older and larger, it is going to be essential to find a way to prevent MetS 
from progressing into DM2 and other health conditions. One of the associations that is 
currently being studied is that between MetS and/or DM2 and hypogonadism.6-11   
There are two main types of hypogonadism, primary and secondary. Primary 
testicular failure results in low testosterone levels, impaired spermatogenesis, and 
elevated gonadotropin levels. Secondary testicular failure is associated with low or low-
normal gonadotropin levels and low testosterone levels.12 It has recently been proposed 
that there is a third type of hypogonadism where gonadotrophin levels may be low to 
normal. This type is associated with chronic illnesses including obesity, metabolic 
syndrome and DM2 among others.13  
There is much controversy about the specific testosterone level that constitutes 
hypogonadism and there is currently no agreed upon standard lab value that designates it. 
Because the effects of testosterone are widespread on the body, designating only a lab 
value to define an abnormality is limiting. Current recommendations are, that late onset 
hypogonadism (LOH), is a clinical and biochemical syndrome associated with advancing 
age; and characterized by symptoms and a deficiency in serum testosterone levels below 
the reference range of a young healthy adult male.14   
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Recent studies15 have looked at the prevalence of LOH in the male population. 
They defined hypogonadism as a total testosterone (TT) < 300 ng/dl and using this 
reference they found that roughly 38.7% of men >45 years are hypogonadal. This 
extrapolates to around 13.8 million men in the US.15 With that large of the population 
having this condition, you would think more men would be receiving testosterone 
replacement already. There is still reluctance on the health care providers’ part to 
prescribe testosterone because it was thought that it could induce prostate cancer, but 
studies seem to be showing that it has no effect on the prostate.16   
There does seem to be an association between the incidence of hypogonadism and 
other conditions. It was found that there was the greatest association of hypogonadism 
with body mass index (BMI), the odds of having the condition were 2.74x more likely in 
a male with a BMI > 25kg/m2 then a male with a BMI of < 25kg/m2. 15 Patients with 
chronic illnesses such as hypertension (HTN), hyperlipidemia, and DM2 also had a 
significantly higher likelihood of having co-morbid hypogonadism.15   
Several studies have been done that have established a link between 
hypogonadism and metabolic syndrome and/or DM2.6-10 With obesity being the number 
one risk factor for both MetS and hypogonadism, Jones proposed a mechanism of action 
that links the two. He proposes that visceral fat has high aromatase activity which 
metabolizes testosterone into estradiol, the more visceral fat, the more the aromatase. The 
testes would not be able to produce enough testosterone to compensate for the loss. This 
fall in testosterone levels leads to a greater activity of lipoprotein lipase causing an 
increased storage of triglycerides and proliferation of adipocytes, thus increasing insulin 
resistance. Normally the body would release more luteinizing hormone to stimulate the 
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testes to produce more testosterone, but that process is blocked by the estradiol and 
adipocytokines.13 According to his theory one exacerbates the other and continues a 
vicious cycle.   
Laaksonen et al9 found that men with a total testosterone level in the lower third 
of the range were 3.5-fold more likely to have metabolic syndrome than men with 
concentrations in the upper third. Hypogonadal patients were found to have a 
significantly higher BMI, larger waist to hip circumference, higher insulin 
concentrations, elevated triglycerides and an increased HOMA value as compared to 
eugonadal men.17 Those characteristics are all components of MetS. Diabetic patients 
have lower total and free testosterone levels in comparison with the rest of the sample 
population and their testosterone levels were inversely related to waist circumference.10 
The Telecom Study,11 performed on healthy adult men, found that plasma testosterone 
levels negatively correlate with age, fasting plasma glucose, 2-h plasma glucose, fasting 
plasma insulin and BMI. These studies all demonstrate that if you have one condition, 
you are much more likely to have the other, so where do we go from here? The next 
logical step is to evaluate if there is any benefit to increasing a man’s testosterone level 
back to physiologic normal. 
 
METHODS 
A comprehensive review of the literature was performed using the data bases: 
CINAHL, ovid - Medline, EBMR Multifile, Web of Science, PubMed and Google 
scholar. The keywords used for the search were: metabolic syndrome, DM2, testosterone, 
therapeutics and hypogonadism. This produced a number of articles on each database; 
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therefore the following inclusion and exclusion criteria were used to narrow the search to 
the appropriate studies. Inclusion criteria: studies involving hypogonadal men with either 
DM2 or MetS or both, using T as a treatment for those disorders. Exclusion criteria: 
studies in another language, studies not using testosterone as a therapy,  studies on 
patients who did not have MetS or DM2, studies on women, studies using non-
hypogonadal men, studies with less than 15 people.  
RESULTS  
After applying these criteria, three studies remained. Of these studies, only one 
was a double blind placebo controlled study,18 the other two were singly binded19 and an 
open label study.20 All the studies were performed in the last eight years in Europe. 
Testosterone Replacement Therapies Effect on Insulin Resistance 
Kapoor et al18 conducted a double blind placebo-controlled crossover study. The trial was 
for a total duration of 7 months with two treatment phases. The participants were 
randomized into either treatment or control, this phase lasted three months, there was a 
washout period of one month and then the groups switched. All subjects were men older 
than 30 years with DM2 and hypogonadism. A total of 27 men were randomized.18  
The treatment consisted of a 200mg testosterone IM injection every two weeks for 
3 months. The placebo group received 0.9% normal saline injection every two weeks for 
3 months. All concomitant oral hypoglyceamic, anti-hypertensive and lipid-lowering 
medications were permitted and continued throughout without any dose adjustments. The 
patients on insulin were allowed to make dose adjustments to prevent hypoglycemia.18   
The following were the statistically significant results when compared to placebo: 
total testosterone and bioavailable testosterone levels increased in treatment group (P 
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0.001), fasting glucose decreased by 1.58 (P 0.03), total cholesterol decreased by 0.4 (P 
0.03), HOMA index was reduced 1.73 (P 0.02) and HbgA1C was reduced 0.37 (P 0.03). 
Waist circumference decreased by 1.63 (P 0.03) and waist/hip ratio decreased by 0.03 (P 
0.01). Of the 10 patients on insulin, 5 patients reduced daily dosages by a mean of 7 
units. There were no changes in PSA, BP, LDL, HDL or TG.18 
The Effect of Diet and Exercise Plus Testosterone on Metabolic Syndrome 
Heufelder et al19 evaluated the effects of adding testosterone gel in addition to diet 
and exercise in the treatment of DM2 and MetS. This study was a single blind study 
where the study personnel, but not the participants, were blinded. It was a randomized 
trial lasting for 52 weeks of 32 hypogonadal males with MetS or newly diagnosed DM2. 
Participants were randomized to diet and exercise only or diet and exercise plus 
testosterone treatment (50mg gel applied daily). The participants were not taking any oral 
antihyperglycemic agents or insulin. All the participants were instructed to have 3 meals 
a day that consisted of a low glycemic load, were low in saturated fats and rich in omega-
3, and they were instructed to attempt to eat 25% fewer calories per meal. For the 
exercise portion of the trial, they were advised to walk for 30 minutes and do 15 minutes 
of muscle building exercise with weights or elastic strings three times per week. Staff 
contacted participants at least twice a week to encourage adherence to the treatment. The 
compliance with D&E was 100%.19 
Both arms of the study had improvement in all areas evaluated, but the 
testosterone treatment group had a greater benefit. In the treatment arm, patients 
testosterone levels increased from 10.5 to 15.4 nmol/L, HgbA1C decreased by 1.3%, 
fasting plasma glucose decreased from 7.9 to 6.1 mmol/L and insulin levels decreased 
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from 113.2 to 40.2 pmol/L. All testosterone patients reached HgbA1C goal of <7% and 
87.5% reached <6.5%. 62.5% of patients no longer matched the International Diabetes 
Federation (IDF) criteria for MetS. Waist circumference declined in both groups, but 
more so in the testosterone group and PSA did not increase in either treatment arm.19   
The control group also saw benefits from this study. With only diet and exercise, 
participants’ testosterone levels increased slightly from 10.4 to 11.2 nmol/L, HgbA1C 
decreased by 0.5%, fasting plasma glucose decreased from 8.3 to 6.6 mmol/L and their 
insulin levels decreased from 116.9 to 60.2 pmol/L. Only 40.4% of the diet and exercise 
patients reached the goal HgbA1C levels <7%, and none reached <6.5%, but 12.5% of 
patients no longer met the IDF criteria for MetS.19 
   
Testosterone, Type 2 Diabetes and Androgen Deficiency 
Boyanove et al20 performed an open-label, randomized, no-treatment controlled 
study of 48 men with DM2 and total testosterone in the lower 1/3 of normal range for 
young adults (<15.1 nmol/L). There were 24 men in the treatment group who received 
oral testosterone undecanoate, 80 mg in the morning and 40 mg at night for three months. 
This was compared to 24 control subjects who received no treatment or placebo.20 
The treatment arm resulted in body weight being reduced by 2.66% (P <0.05) and 
BMI by 3.2%. Waist/hip ratio decreased by 3.96% (P <0.05) and body fat decreased by 
5.6% (P <0.05). Fasting, postprandial and mean daily blood glucose values dropped 
significantly (P <0.05) and HgbA1C had an absolute decrease of 1.8% (P <0.05). There 
were no significant changes in systolic or diastolic BP or in serum total cholesterol. All 
symptoms of androgen deficiency (nervousness, insomnia, fatigue and decreased libido) 
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were significantly improved in the treatment group. As expected, total serum testosterone 
increased in the treatment group and there were no adverse events reported during the 
study.20   
DISCUSSION 
The results of these three studies, while limited, are promising. There is clearly a 
link between low testosterone levels and increasing levels of insulin, glucose and BMI 11 
in the aging male. Finding new ways to combat these issues will lead to a healthier 
society.   
Effects on Glycemic Control 
One of the most harmful and difficult aspects to manage in DM2 or MetS are 
glucose levels. The damage which elevated glucose levels cause on all organ systems in 
the body takes a huge toll on a person’s health and is usually irreversible. However just a 
small decrease in circulating glucose can have substantial health benefits in that it can 
slow the progression of the disease, but reaching a target HgbA1C goal of < 7% takes 
making major lifestyle changes and is very therefore difficult.21   
Testosterone replacement therapy improved HgbA1C in all the studies. 
Participants in the Heufelder et al19 study all met the HgbA1C goal of <7% with 87.5% of 
the testosterone group reaching a goal of <6.5%.  None of the control group were able to 
reach a goal of <6.5%. Another study20 showed a drop in HgbA1C from an average of 
10.4 to 8.6% after 3 months of treatment with testosterone, placebo only decreased from 
10.3 to 9.9%. A drop in HbgA1C from 10-8% lowers the average circulating glucose 
from 240 mg/dl to 183 mg/dl.22 (Table 2) The third study18 also demonstrated a drop in 
HgbA1C as a consequence of a statistically significant drop in fasting glucose levels, P 
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0.03. Kapoor et al18 also had a reduction in insulin dosage in the treatment arm of the 
study.  Of the 10 patients on insulin, five reduced their daily dosage by a mean of 7 units. 
Reducing circulating glucose levels can slow or prevent the progression of MetS to DM2.  
The ISA, ISSAM, EAU, EAA, and ASA have issued guidelines14 in regards to 
testosterone replacement and diabetes within the last couple of years. They have 
concluded that serum testosterone levels should be measured in men with DM2 with 
symptoms suggestive of testosterone deficiency (Level 2b, Grade A) (Table 3). They go 
on to say that in men with hypogonadism and diabetes and/or metabolic syndrome, the 
testosterone treatment for traditional hypogonadal symptoms may have other unproven 
benefits on their metabolic status (Level 2a, Grade B).14   
Body Composition 
According to the National Health Statistics Reports,5 abdominal obesity is the 
number one risk factor for developing metabolic syndrome. Diabetic men have a higher 
BMI and waist to hip ratio than nondiabetics8 and hypogonadal patients have a 
significantly higher BMI and waist to hip ratio than eugonadal men.17 Both 
hypogonadism and metabolic derangements are associated with an increasing waist line. 
Visceral fat appears to be more metabolically active then subcutaneous fat and it 
drains directly into the liver which exposes it to more free fatty acids, thus increasing 
hepatic insulin resistance.13 These are the factors that make reducing abdominal fat so 
important to stopping the progression of MetS to DM2. A waist to hip ratio of >0.9 in 
men seemed to have a greater correlation to MetS and subsequent risk factors for 
cardiovascular morbidity and mortality than a BMI > 30 kg/m2 did.23 After only 3 months 
of treatment with testosterone, waist to hip ratio decreased from 1.01 to 0.97 in one 
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study20 and 1.02 to 0.99 in the other study.18 The 52 week study19 also showed an 
improvement in waist to hip ratio, but did not specify how much of an improvement there 
was.   
One of the most promising outcomes of all the studies was in the 52 week study19 
where 62.5% of men treated with diet and exercise plus testosterone no longer met the 
International Diabetes Federation (IDF) definition for MetS, compared to 12.5% of diet 
and exercise only. This elimination of MetS is important because patients with MetS have 
a threefold higher likelihood of developing coronary heart disease (CHD), MI, and stroke 
then patients without MetS. They were also more likely to die within the six year follow 
up period than patients without MetS.23   
The current recommendation is that in men with hypogonadal values, testosterone 
replacement improves body composition (Level 1b, Grade A).14 Testosterone 
supplementation is by no means a magic bullet, but it does warrant more investigation. 
As Heufelder et al19 demonstrated there is significant benefit to the old adage, “move 
more, eat less” but by replacing a man’s T level back to physiological norms, there is an 
even greater benefit.  
Adverse Outcomes 
Hormone replacement therapy (HRT) has been a very controversial topic in the 
health care field. The controversy has always been with women and there has not been 
much investigation into male HRT. Preliminary studies appear to be promising, but the 
possible adverse outcomes must always be examined. The most worrisome outcome 
would be testosterone therapy inducing prostate cancer or converting subclinical prostate 
cancer into clinically detectable cancer. A randomized control trial of 41 men16 looked at 
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the development of prostate cancer after testosterone therapy. They found that of the 41 
men, six developed prostate cancer, four were in the control group and two were in 
treatment group.  Of the studies evaluated today,18-20 none of the participants had any 
adverse outcomes and there was no increase in circulating PSA levels in the studies that 
measured it.1918   
The ISA, ISSAM, EAA and ASA14 have found that there is no evidence that 
testosterone treatment will convert subclinical prostate cancer to clinically detectable 
prostate cancer (level 4, grade C), but there is unequivocal evidence that testosterone can 
stimulate the growth and aggravate symptoms in men with locally advanced or metastatic 
prostate cancer (level 2a, grade A). They also suggest that in hypogonadal men >45 years 
the risks and benefits of testosterone substitution should be discussed and they should be 
carefully monitored for prostate safety during treatment (Level 3, Grade A).14  
Testosterone replacement therapy is contraindicated in men with prostate or breast cancer 
(Level 3, Grade A). It is also recommended that men with significant erythrocytosis, 
untreated obstructive sleep apnea, and untreated severe congestive heart failure not be 
started on testosterone replacement until co-morbid conditions are resolved.14   
Study Limitations 
These were by no means perfect studies. One of the main limitations of these 
studies was the short duration of treatment. The Heufelder et al19 study was the longest at 
52 weeks with the other studies18, 20 only having a treatment phase of three months. The 
ideal study would run for at least five years of treatment.   
There was also discrepancy in how the testosterone was administered.  Each study 
used a different kind of testosterone, one used gel,19 another IM18 and the last one used an 
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oral T.20 Each route of delivery has different absorption rates and can have its own gamut 
of side effects. In future studies the route of administration of testosterone needs to be 
standardized.   
Only one of the studies was a placebo controlled double blind study,18 one was an 
open study20 and the other was only singly blinded.19 The ideal study is always a double 
blind placebo controlled study. There were definite limitations to the current studies, but 
they have established the need for further evaluation.   
The ideal study would be a double blind, placebo controlled study of middle aged 
men with metabolic syndrome, not currently on any treatment, with a study length of 5 
years. This study would look at the progression to DM2 in placebo compared to treatment 
group, effects on the prostate, hyperviscosity, HgbA1C levels, and CV effects. Men in 
treatment group would have their testosterone levels replaced to physiological norms and 
would all have the same method of testosterone deposition.   
 
CONCLUSION 
There is a clearly defined link between hypogonadism and metabolic syndrome. 
Replacing a man’s testosterone levels back to physiologic norms appears to have many 
beneficial results. One of the benefits appears to be on metabolic derangements which 
can lead to DM2. Early research has shown, in hypogonadal men treated with T, a 
reversal of metabolic syndrome in some,19 decrease in waist circumference,18, 20 improved 
HgbA1C18-20 and improved fasting insulin levels.18, 19 All of these factors, left untreated, 
increase a man’s risk of ASCVD.23 Improvement of these risk factors can substantially 
improve a patient’s quality and quantity of life.   
19 
 
There are known risk factors to replacing testosterone levels to supraphysiologic 
levels, but initial studies have shown that replacement to physiologic norms has few side 
effects.16 It is currently recommended that in men with DM2 who are displaying 
symptoms of hypogonadism their testosterone levels are checked.14 They also state that 
testosterone replacement may have other unproven benefits on metabolic status and the 
risks and benefits should be discussed with all men before initiating treatment.14 The 
studies evaluated,18-20 appear to show that the benefits of testosterone replacement 
currently outweigh the potential risks and as with any treatment in medicine informed 
consent is key.   
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TABLES 
TABLE 1. Criteria for Clinical Diagnosis of 
Metabolic Syndrome24 
Measure (any 3 of 5 constitute 
diagnosis of metabolic syndrome) 
Categorical Cutpoints 
 
Elevated waist circumference*† ≥102 cm (≥40 inches) in men 
≥88 cm (≥35 inches) in women 
 
Elevated triglycerides ≥150 mg/dL (1.7 mmol/L) 
or 
On drug treatment for elevated 
triglycerides‡ 
 
Reduced HDL-C <40 mg/dL (1.03 mmol/L) in men 
<50 mg/dL (1.3 mmol/L) in women 
or 
On drug treatment for reduced 
HDL-C‡ 
 
Elevated blood pressure ≥130 mm Hg systolic blood pressure 
or 
>85 mm Hg diastolic blood pressure 
or 
On antihypertensive drug treatment in 
a patient with a history of 
hypertension 
 
Elevated fasting glucose ≥100 mg/dL 
or 
On drug treatment for elevated 
glucose 
 
*To measure waist circumference, locate top of right iliac crest. Place ameasuring tape in a horizontal plane around abdomen at level 
of iliac crest. Before reading tape measure, ensure that tape is snug but does not compress the skin and is parallel to floor. 
Measurement is made at the end of a normal expiration. 
†Some US adults of non-Asian origin (eg, white, black, Hispanic) with marginally increased waist circumference (eg, 94–101 cm [37–
39 inches] in men and 80–87 cm [31–34 inches] in women) may have strong genetic contribution to insulin resistance and should 
benefit from changes in lifestyle habits, similar to men with categorical increases in waist circumference. Lower waist circumference 
cutpoint (eg, _90 cm [35 inches] in men and _80 cm [31inches] in women) appears to be appropriate for Asian Americans. 
‡Fibrates and nicotinic acid are the most commonly used drugs for elevated TG and reduced HDL-C. Patients taking one of these 
drugs are presumed to have high TG and low HDL 
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Table 2—Estimated average glucose22 
 
A1C (%)  mg/dl*  mmol/l† 
5  97 (76–120)   5.4 (4.2–6.7) 
6  126 (100–152)  7.0 (5.5–8.5) 
7  154 (123–185)  8.6 (6.8–10.3) 
8  183 (147–217)  10.2 (8.1–12.1) 
9  212 (170–249)  11.8 (9.4–13.9) 
10  240 (193–282)  13.4 (10.7–15.7) 
11  269 (217–314)  14.9 (12.0–17.5) 
12  298 (240–347)  16.5 (13.3–19.3) 
 
Data in parentheses are 95% CIs. *Linear regression 
eAG (mg/dl)_28.7_A1C_46.7. †Linear regression 
eAG (mmol/l) _ 1.5944 _ A1C _ 2.5944.  
 
 
 
 
 
 
 
 
 
Table 3- Level of evidence and grade of recommendation utilized in the 
recommendations14 
 
Level Type of evidence 
 
1a - Evidence obtained from meta-analysis of randomized trials 
1b - Evidence obtained from at least one randomized trial 
2a - Evidence obtained from one well-designed controlled study without randomization 
2b - Evidence obtained from at least one other type of well-designed quasi-experimental 
study 
3 - Evidence obtained from well-designed non-experimental studies, such as comparative 
studies, correlation studies, and 
case reports 
4  - Evidence obtained from expert committee reports or opinions or clinical experience 
of respected authorities 
 
Grade Nature of recommendations 
 
A - Based on clinical studies of good quality and consistency addressing the specific 
recommendations and including at least 
one randomized trial 
B - Based on well-conducted clinical studies, but without randomized clinical trials 
C - Made despite the absence of directly applicable clinical studies of good quality 
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Table 4 – Summary Matrix of Reviewed Literature 
 
 
 
Table 5 – Results Summary 
 Kapoor et al18 Heufelder et al19 Boyanov et al20 
  Treatment  Control Ttreatment Control Treatment  Control 
HgbAlC % 7.28% to 6.91% 7.28% to 7.25% 7.5% to 
6.3% 
7.5% to 
7.1% 
10.4% to 
8.6% 
10.3% to 
9.9% 
Fasting Glucose 
mmol/L 
7.83 to 7.38 7.6 to 8.73 7.9 to 6.1  8.3 to 6.6  8.0 to 6.0 8.4 to 8.0 
Fasing insulin 
pmol/L 
13.68 mlU/l to 11.76 
mlU/l 
12.37 mlU/l to 12.36 
mlU/l 
113.2 to 
40.2 
116.9 to 
60.2 
Not reported Not reported 
BMI (kg/m2) 33.28 to 33.62 32.85 to 32.97 Not reported Not 
reported 
31.08 to 
30.08 
31.01 to 
30.88 
W/H ratio 1.02 to 0.99 Not reported Not reported Not 
reported 
1.01 to 0.97 1.03 to 1.02 
 
 
Author Yr.  
published 
Patients/  
Population 
Intervention Comparison Outcome(s) Study type Validity 
(Jadad 
score) 
D Kapoor 
et al18 
 
 
2006 
 
Men 30 yrs or 
greater w/ type 2 
DM and 
hypogonadism 
 
IM testosterone 
200 mg q 2 
weeks x 3 mo 
 
IM saline q 2 
weeks x 3 
mo 
 
Testosterone 
replacement 
improved insulin 
resistance and 
glycemic control.   
 
Double blind 
placebo-
controlled 
crossover 
study 
 
5/5 
Heufelder 
et al19 
 
 
2009 
 
32 hypogonadal 
males w/ 
metabolic 
syndrome and 
newly diagnosed 
type 2 DM 
 
Diet and 
exercise plus 
testosterone gel 
50 mg qd 
 
Diet and 
exercise only 
 
Both groups saw 
an improvement in 
HgbA1C and the 
compents of MetS, 
but an even greater 
improvement was 
observed with the 
addition of 
testosterone. 
 
Randomized 
single blinded 
study 
 
3/5 
Boyanov 
et al20 
 
2003  
48 men with DM2 
and serum T 
levels below the 
normal range for 
young adults or in 
the lower 1/3 of 
this range. 
 
Oral 
testosterone 
undecanoate x 
3 mo. 80 mg 
qam, 40 mg q 
pm everyday 
 
No treatment 
 
Testosterone 
treatment 
improved 
metabolic control 
of DM2, decreased 
visceral obesity 
and lowered 
HgbA1C values. 
Open-label, 
randomized, 
no-treatment 
controlled 
study. 
2/5 
